Skip to main content

Table 2 Antimicrobial susceptibility profiles of the K. pneumoniae and E. coli strains used in this study

From: Co-introduction of plasmids harbouring the carbapenemase genes, blaNDM-1 and blaOXA-232, increases fitness and virulence of bacterial host

StrainMIC (mg/L) (antimicrobial susceptibility category)a, b
Donor (K. pneumoniae M5)> 64 (R)> 64 (R)> 128 (R)> 64 (R)> 64 (R)> 64 (R)> 128 (R)> 64 (R)8 (I)> 32/608 (R)> 256/4 (R)0.5 (S)
Recipient (E. coli DH5α)0.125 (S)0.06 (S)0.125 (S)0.5 (S)4 (S)1 (S)4 (S)0.06 (S)0.5 (S)0.25/4.75 (S)4/4 (S)0.06 (S)
DH5α::pM5_NDM4 (R)0.5 (S)> 128 (R)> 64 (R)> 64 (R)> 64 (R)> 128 (R)0.06 (S)0.5 (S)> 32/608 (R)> 256/4 (R)0.125 (S)
DH5α::pM5_OXA1 (S)0.25 (S)4 (S)0.5 (S)> 64 (R)4 (S)16 (S)0.06 (S)0.5 (S)2/38 (S)> 256/4 (R)0.06 (S)
4 (R)1 (S)> 128 (R)> 64 (R)> 64 (R)> 64 (R)> 128 (R)0.06 (S)0.5 (S)> 32/608 (R)> 256/4 (R)0.06 (S)
  1. aIMI imipenem, MRP meropenem, CTX cefotaxime, CAZ ceftazidime, AMP ampicillin, GEN gentamicin, AMK amikacin, CIP ciprofloxacin, TET tetracycline, SXT trimethoprim-sulfamethoxazole, P/T piperacillin-tazobactam, CL colistin
  2. bR resistant, I intermediate-resistant, S susceptible